Filing Flows › ImmunityBio (IBRX) › Q1 2026
ImmunityBio (IBRX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
ImmunityBio (IBRX) reported revenue of $44.2M for the first quarter 2026 (Q1 2026), +168% from a year earlier and +15% from the quarter before. Operating margin was -157.9%.
ImmunityBio, Q1 2026: revenue $44.2M (+168% year over year), operating margin -157.9%, net loss $633M, operating cash flow −$75.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $44.2M | +15% | +168% |
| Operating profit | −$69.8M | — | — |
| Net earnings | −$633M | — | — |
| Operating cash flow | −$75.4M | — | — |
What changed
Revenue was $44.2M in Q1 2026, up 168% year over year and up 15% from the previous quarter. Product revenue, net was the largest line at 100% of revenue. Product revenue, net added $27.7M year over year (up 168%), 100% of the total change.
Operating costs exceeded revenue by $69.8M, an operating margin of -157.9%. Total costs grew 41% against revenue growth of 168%. The fastest-growing cost line was Cost of revenue (+310%). The quarter ended with a net loss of $632.8M, wider than the previous quarter's $62.0M loss. Net interest and other expense of $563.0M was the main reason.
Operating cash flow was −$75.4M. Non-cash charges added back $4.4M of depreciation and amortization and $8.2M of share-based compensation. Working capital and other items added $544.9M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$77.1M.
Questions
What was ImmunityBio's revenue in the first quarter 2026?
ImmunityBio (IBRX) reported revenue of $44.2M for the first quarter 2026 (Q1 2026), +168% from a year earlier and +15% from the quarter before.
Was ImmunityBio profitable in the first quarter 2026?
Operating loss was $69.8M (-157.9% of revenue) and net loss $633M.
Source: ImmunityBio 10-Q on SEC EDGAR.